Chief Executive Officer
Boston, Massachusetts, Us
As Chief Executive Officer, I led the transformation of an academia focused life sciences company into the industry’s leading bioinformatics ecosystem provider to both commercial biopharma and government programs, evolving the company culture, strategy and operational/financial disciplines, generating exceptional growth in revenue / gross margin and significantly increasing valuation in less than 4 years, resulting in the acquisition by Summa Equity. Seven Bridges (acquired by Summa Equity in 2022) enabled researchers worldwide toextract meaningful insights from genomic data in order to advance precision medicine with offices in the US, UK, Serbia, Turkey and throughout central Europe. Our complete bioinformatics ecosystem consists of a compliant analytics platform, seamless data and automation, transforming analytic solutions, and expert scientific services. This holistic approach to bioinformatics is enables researchers - at the world’s leading academic, biotechnology, government, medical centers, and pharmaceutical entities - to increase R&D efficiency, enhance hypothesis resolution, isolate critical biomarkers, and even turn failing clinical into successes. Ultimately, reducing the time, cost, and risk associated with new product development in order to bring more life-changing products to market earlier. In doing so, the Seven Bridges team supports thousands of researchers in biopharma, government, and academia, as well as some of the world's largest national genomics research programs, including: >20 of the top 30 largest commercial biopharma companies, many bio-techs, and various programs under NIH, NHLBI, NCI, NIAID, NIA, VA, Genomics England, UK Biobank and others.